Stoke Therapeutics (STOK) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 3[1], 1 Phase 2[2].
Trial NCT06872125[4] evaluates zorevunersen in Dravet Syndrome with a target enrollment of 170 participants.
STOK has 15 Form 4 insider filings recorded at the SEC in the past 30 days[5].